Kolexia
Breton-Callu Christel Oncologie radiothérapie
Breton-Callu Christel
Oncologie radiothérapie
Centre Hospitalier de Brive
Brive-la-Gaillarde, France
57 Activités
1 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Tumeurs du sein Carcinome canalaire du sein Carcinome épidermoïde Poumon radique Hypertrophie Carcinomes Tumeurs des glandes endocrines Tumeurs radio-induites Ostéogenèse imparfaite

Collaborateurs

Voir plus
Kamsu Kom Leopold
Kamsu Kom Leopold
Centre Hospitalier de Brive, Brive-la-Gaillarde, France
Nivet Alexandre
Nivet Alexandre
Centre Hospitalier de Brive, Brive-la-Gaillarde, France
Vayre Laure
Vayre Laure
Centre Hospitalier de Brive, Brive-la-Gaillarde, France
Madranges Nicolas
Madranges Nicolas
Centre Hospitalier Libourne, Libourne, France

Industries

Voir plus
B3TSI
10 collaboration(s)
Dernière en 2023
AstraZeneca
8 collaboration(s)
Dernière en 2023
Janssen
8 collaboration(s)
Dernière en 2023
MSD
7 collaboration(s)
Dernière en 2023

Dernières activités

Voir plus
Ville de Brive - Ce samedi 15 Octobre le coup d'envoi du...
Facebook   18 octobre 2022
Quality assurance program and early toxicities in the phase III BONBIS randomized trial evaluating the role of a localized radiation boost in ductal carcinoma in situ.
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology   24 septembre 2021
NIMFEA: A Randomized Multicenter Phase II Study Identifying Hormone Sensitivity Profiles and Evaluating the Efficacy of Anastrozole and Fulvestrant in the Neo-adjuvant Treatment of Operable Breast Cancer in Postmenopausal Women.
Essai Clinique (Unicancer)   04 juin 2021
HORGEN: Response to Neoadjuvant Treatment With Anti-aromatase Anastrozole and Anti-estrogen Fulvestrant: a Randomized Phase II Study in Postmenopausal Patients With Hormone-sensitive Non-metastatic Breast Cancer and an Exploratory Study of Molecular Signatures of Response.
Essai Clinique (Institut Bergonié)   03 février 2021
Predictive factors of 5-year relapse-free survival in HR+/HER2- breast cancer patients treated with neoadjuvant endocrine therapy: pooled analysis of two phase 2 trials.
British journal of cancer   31 janvier 2020
TARGIT-B: An International Randomised Controlled Trial to Compare Targeted Intra-operative Radiotherapy Boost With Conventional External Beam Radiotherapy Boost After Lumpectomy for Breast Cancer in Women With a High Risk of Local Recurrence.
Essai Clinique (University College, London)   10 juillet 2019
5-years RFS and prognostic factors study in HR-positive HER2-negative breast cancer patients treated with neoadjuvant endocrine therapy : Pooled analysis of two phase II trials
12e Conférence francophone d’Épidémiologie clinique 25e Journée des statisticiens des Centres de lutte contre le cancer   01 mai 2018
Lung dose constraints for normo-fractionated radiotherapy and for stereotactic body radiation therapy.
Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique   05 septembre 2017
Factors predictive of locoregional recurrence following neoadjuvant chemotherapy in patients with large operable or locally advanced breast cancer: An analysis of the EORTC 10994/BIG 1-00 study.
European journal of cancer (Oxford, England : 1990)   18 mai 2017
Practice evolution of hypofractionation in breast radiation therapy and medical impact.
Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique   23 juin 2016